← 返回博客Industry News

The EU SoHO Regulation: What Cryobanks, Clinics and Donor Agencies Should Prepare for Before 2027

3 November 2026

A new framework for substances of human origin

For close to two decades, the handling of human tissues and cells in the European Union, including reproductive cells such as donor oocytes, has been shaped largely by the EU Tissues and Cells Directive and the national laws that implemented it. Because a directive is transposed separately by each Member State, the practical rules have varied from country to country, and many cryobanks and clinics working across borders have had to navigate several slightly different interpretations of the same underlying framework.

That is now changing. In 2024 the EU adopted Regulation (EU) 2024/1938 on standards of quality and safety for substances of human origin intended for human application, usually shortened to the SoHO Regulation. It brings blood, tissues, cells and other substances of human origin, including those used in medically assisted reproduction, under a single framework. Unlike a directive, a regulation applies directly in every Member State, and most of its provisions are scheduled to apply from 2027, with certain transitional arrangements.

This article is a general overview for professionals in the donor oocyte sector. It is not legal or regulatory advice. The text of the Regulation, accompanying implementing acts and national guidance should be reviewed with your own legal and regulatory counsel, and any clinical questions should be directed to your clinic and medical team.

Why the shift from directive to regulation matters

The most visible change is structural. A directly applicable regulation is intended to reduce the differences between national regimes, which in principle should make cross-border work within the EU more predictable. For a cryobank sourcing from one Member State and supplying clinics in several others, a more harmonised baseline could simplify how documentation and quality systems are aligned across partners.

Harmonisation is unlikely to be total, however. Member States generally keep room to set additional national rules in certain areas, and ethical questions around reproductive medicine, such as donor anonymity, compensation and eligibility, remain heavily shaped by national law. Organisations should therefore expect a common EU layer combined with continuing national variation, and plan their compliance reviews on that basis.

Key themes for the donor oocyte sector

Several broad themes in the SoHO Regulation are likely to be relevant to anyone working with donor oocytes. One is a stronger emphasis on donor protection, reflected in provisions concerned with the health and wellbeing of donors as well as recipients. Another is a broader approach to which activities and organisations fall within scope, using the concept of SoHO entities and SoHO establishments, which may affect how some organisations that previously sat at the edges of the old framework are classified.

The Regulation also places weight on quality management, traceability and vigilance, building on principles already familiar from the tissues and cells framework. It provides for greater coordination between national competent authorities and for an EU-level digital platform intended to support information sharing. In addition, it gives a role to expert bodies in developing technical guidance, which means that some of the practical detail will continue to evolve after the main application date.

How each of these themes translates into day-to-day obligations for a specific organisation depends on its activities, its location and how national authorities apply the rules. That assessment belongs with your regulatory advisers, but understanding the themes early helps teams ask the right questions.

What cryobanks may want to review

For cryobanks, the natural starting point is the existing quality management system. Teams may find it useful to map their current procedures for donor documentation, coding, traceability, storage and release against the themes of the new framework, and to note where internal processes rely on national rules that could be replaced or supplemented. Supplier agreements are another area worth revisiting, particularly clauses on documentation, notification of adverse events and the allocation of responsibilities between partners.

Cryobanks that supply outside the EU, for example to the UK, the USA, Australia or China, should also bear in mind that the SoHO Regulation does not replace the import rules of those destinations. Each route continues to require its own regulatory review.

What fertility clinics may want to review

Fertility clinics within the EU that receive or use donor oocytes will typically want their quality, laboratory and regulatory leads to follow guidance from their national competent authority as the application date approaches. Practical preparation can include checking how the clinic's own registration or authorisation may be affected, reviewing incoming documentation requirements for donor material, and confirming how vigilance reporting is expected to work under the new arrangements.

Clinics that import donor oocytes from outside the EU should pay particular attention to how import activities are addressed. Requirements in this area can be detailed, and the right approach for a given clinic should be confirmed with counsel rather than inferred from general summaries.

What donor agencies may want to review

Donor agencies occupy different positions depending on the services they provide, and the broader scope of the new framework makes it worth checking how an agency's activities may be classified. Agencies that support donor recruitment, coordination or documentation on behalf of clinics may wish to review their contracts with clinic partners, their record-keeping practices and their handling of donor information, especially in light of the Regulation's focus on donor protection.

Because agencies frequently work across several countries, they may also benefit from building a simple matrix of which partners operate under which national rules, so that changes can be tracked in one place as guidance is published.

Preparing without overreacting

With a date some time away and technical guidance still developing, the sensible approach for most organisations is steady preparation rather than urgent overhaul. A short internal gap review, a named owner for regulatory monitoring, regular check-ins with national competent authority publications and professional society updates, and early conversations with key partners can go a long way. Professional societies in reproductive medicine have published summaries and commentary that many teams find useful as a starting point, alongside the official text.

How B2B platforms fit in

Closed B2B platforms such as DonorMatchPro are designed to connect cryobanks, fertility clinics and donor agencies in a professional environment and to keep donor oocyte profiles, partner communication and coordination records organised in one place. Structured, consistent records can make it easier for organisations to respond to partner questions and to support their own compliance work. A platform does not, however, determine an organisation's regulatory status or replace its own legal review, quality system or clinical judgement.

Other organisations operate in the donor gamete space, including Cryos International, Ovoria and Ovogene, each with its own model and focus, and cryobanks and clinics typically evaluate a range of partners and tools according to their markets and internal processes.

Key takeaways

The SoHO Regulation is one of the most significant changes to the EU framework for tissues and cells in many years, and it is relevant to the donor oocyte sector. Most provisions are scheduled to apply from 2027, national variation will remain in important areas, and further technical guidance is expected. Cryobanks, clinics and agencies can prepare by understanding the main themes, reviewing their quality systems and partner agreements, and monitoring guidance from their national authorities. For anything legal, regulatory or tax-related, confirm with your own counsel; for anything clinical, consult your clinic and medical team.